tolebrutinib
sanofi
['tolebrutinib']
aan 2023: tolebrutinib safely lowering relapse rates at 2.5 years of use | phase 2b extension trial update has patients on 60 mg dose | #multiplesclerosis news today 
I #write a blog about #MultipleSclerosis .Part time #writer DX with #RRMS in 2008. now #SPMS 🙄 https://t.co/9rplaxege9